ALEXIDINE

ID: ALA1195210

Max Phase: Phase

Molecular Formula: C26H56N10

Molecular Weight: 508.80

Molecule Type: Small molecule

Associated Items:

Representations

Synonyms (5): Bisguadine | COMPOUND 904 | STERWIN 904 | WIN 21,904 | WIN-21904
Synonyms from Alternative Forms(5):

    Canonical SMILES:  CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC

    Standard InChI:  InChI=1S/C26H56N10/c1-5-9-15-21(7-3)19-33-25(29)35-23(27)31-17-13-11-12-14-18-32-24(28)36-26(30)34-20-22(8-4)16-10-6-2/h21-22H,5-20H2,1-4H3,(H5,27,29,31,33,35)(H5,28,30,32,34,36)

    Standard InChI Key:  LFVVNPBBFUSSHL-UHFFFAOYSA-N

    Associated Targets(Human)

    Histone deacetylase 6 20808 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Solute carrier family 22 member 3 143 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    POU domain, class 2, transcription factor 1 93 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Associated Targets(non-human)

    Pseudomonas aeruginosa 123386 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Streptococcus mutans 2687 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    SARS-CoV-2 38078 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Providencia stuartii 425 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Molecule Features

    Natural Product: YesOral: NoChemical Probe: NoParenteral: No
    Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
    Chirality: NoAvailability: NoProdrug: No

    Drug Indications

    MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

    Mechanisms of Action

    Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

    Properties

    Molecular Weight: 508.80Molecular Weight (Monoisotopic): 508.4689AlogP: 4.26#Rotatable Bonds: 19
    Polar Surface Area: 167.58Molecular Species: BASEHBA: 4HBD: 10
    #RO5 Violations: 2HBA (Lipinski): 10HBD (Lipinski): 10#RO5 Violations (Lipinski): 2
    CX Acidic pKa: CX Basic pKa: 12.20CX LogP: 5.53CX LogD: -3.60
    Aromatic Rings: 0Heavy Atoms: 36QED Weighted: 0.07Np Likeness Score: 0.24

    References

    1. Fraud S, Campigotto AJ, Chen Z, Poole K..  (2008)  MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor.,  52  (12): [PMID:18838593] [10.1128/aac.01072-08]
    2. USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date, 
    3. Warner VD, Lynch DM, Kim KH, Grunewald GL..  (1979)  Quantitative structure-activity relationships for biguanides, carbamimidates, and bisbiguanides as inhibitors of Streptococcus mutans No. 6715.,  22  (4): [PMID:430476] [10.1021/jm00190a006]
    4. Ellen Van Damme.  (2021)  Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity,  [10.6019/CHEMBL4651402]
    5. Bernhard Ellinger, Justus Dick, Vanessa Lage-Rupprecht, Bruce Schultz, Andrea Zaliani, Marcin Namysl, Stephan Gebel, Ole Pless, Jeanette Reinshagen, Christian Ebeling, Alexander Esser, Marc Jacobs, Carsten Claussen, and Martin Hofmann-Apitius.  (2021)  HDAC6 screening dataset using tau-based substrate in an enzymatic assay yields selective inhibitors and activators,  [10.6019/CHEMBL4808148]
    6. Gebauer L, Jensen O, Brockmöller J, Dücker C..  (2022)  Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.,  65  (18.0): [PMID:36067397] [10.1021/acs.jmedchem.2c01075]
    7. Grytsai O, Myrgorodska I, Rocchi S, Ronco C, Benhida R..  (2021)  Biguanides drugs: Past success stories and promising future for drug discovery.,  224  [PMID:34364161] [10.1016/j.ejmech.2021.113726]